NLRP3 and acute kidney injury: As a first-in-class specific inhibitor of the NLRP3 inflammasome, Dapansutrile (OLT1177) has shown considerable therapeutic promise across a diverse spectrum of disease models.In the field of acute kidney injury (AKI) (Elsayed et al., 2021), studies have confirmed its efficacy in suppressing NLRP3 inflammasome activation triggered by various etiologies including ischemia/reperfusion, folic acid induction, or hemolytic transfusion reactions.